Abstract:Sleep disorders are prevalent among stroke survivors and impede stroke recovery, yet the mechanisms are unclear and no approved drugs in stroke care. We found stoke causes dysfunction of the suprachiasmatic nucleus (SCN). The hypnotic drug zolpidem restores SCN activity, and rapidly relieves post‐stroke sleep problems, implying its therapeutic promise. Aims Sleep disorders are prevalent among stroke survivors and impede stroke recovery, yet they are still insufficiently considered in the management of stroke patients, and the mechanisms by which they occur remain unclear. There is evidence that boosting phasic GABA signaling with zolpidem during the repair phase improves stroke recovery by enhancing neural plasticity; however, as a non‐benzodiazepine hypnotic, the effects of zolpidem on post‐stroke sleep disorders remain unclear. Method Transient ischemic stroke in male rats was induced with a 30‐minute middle cerebral artery occlusion. Zolpidem or vehicle was intraperitoneally delivered once daily from 2 to 7 days after the stroke, and the electroencephalogram and electromyogram were recorded simultaneously. At 24 h after ischemia, c‐Fos immunostaining was used to assess the effect of transient ischemic stroke and acute zolpidem treatment on neuronal activity. Results In addition to the effects on reducing brain damage and mitigating behavioral deficits, repeated zolpidem treatment during the subacute phase of stroke quickly ameliorated circadian rhythm disruption, alleviated sleep fragmentation, and increased sleep depth in ischemic rats. Immunohistochemical staining showed that in contrast to robust activation in para‐infarct and some remote areas by 24 h after the onset of focal ischemia, the activity of the ipsilateral suprachiasmatic nucleus, the biological rhythm center, was strongly suppressed. A single dose of zolpidem significantly upregulated c‐Fos expression in the ipsilateral suprachiasmatic nucleus to levels comparable to the contralateral side. Conclusion Stroke leads to suprachiasmatic nucleus dysfunction. Zolpidem restores suprachiasmatic nucleus activity and effectively alleviates post‐stroke sleep disturbances, indicating its potential to promote stroke recovery.

Sleep Disorders in Patients with Ischemic Stroke: Pathophysiological Mechanisms and Treatment

Sleep Disorders after Acute Ischemic Stroke

Deciphering Post-Stroke Sleep Disorders: Unveiling Neurological Mechanisms in the Realm of Brain Science

Sleep Disorders in Stroke: An Update on Management.

Sleep apnoea and ischaemic stroke: current knowledge and future directions

Research progress of nursing care for patients with post-stroke sleep disorders

The multifaceted aspects of sleep and sleep-wake disorders following stroke

Interactions between remote ischemic conditioning and post-stroke sleep regulation

Stroke: What's Sleep Got to Do With It?

Sleep-wake disturbances after stroke

Stroke and Sleep-Wake Disturbance

Pathological Mechanism and Drug Therapy for Post Stroke Depression

Sleep disorders as both risk factors for, and a consequence of, stroke: A narrative review

Alleviating sleep disturbances and modulating neuronal activity after ischemia: Evidence for the benefits of zolpidem in stroke recovery

Insomnia and Sleep-Related Breathing Disorders: New Risk Factors for Ischemic Stroke

Cognitive Impairment and Sleep Disturbances after Minor Ischemic Stroke

The prevalence and clinical significance of sleep disorders in acute ischemic stroke patients—a questionnaire study

Sleep architecture in acute stroke

Relation between sleep disorders and post-stroke cognitive impairment

Sleep and Stroke: New Updates on Epidemiology, Pathophysiology, Assessment, and Treatment

Obstructive sleep apnea and stroke: The mechanisms, the randomized trials, and the road ahead